Clinical trials: Cholangiocarcinoma Cancer
Biliary Tract Carcinoma
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma.
- Trial name
- NCT04924062
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 22 sites in China
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer, Bile Duct Cancer
Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy
The purpose of this study is to determine which stent type is effective in the decrease of postoperative stay and complications across pancreaticojejunostomy after pancreaticoduodenectomy.
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Ampullary Cancer, Pancreatitis
- Trial name
- NCT00628186
- Testing
- external drainage tube [polyethylene pancreatic drainage tube], internal drainage tube [polyethylene pancreatic drainage tube]
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Wakayama Medical University
Cholangiocarcinoma
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA).
- Trial name
- ProvIDHe (NCT05876754)
- Testing
- Ivosidenib Oral Tablet
- Where
- 84 sites in Armenia, Australia and 14 more
- Volunteers
- 299 people
- Sponsor
- Servier Affaires Médicales
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangiocarcinoma. Each cycle will be 3 weeks.
- Conditions
- Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
- Trial name
- NCT06728410
- Testing
- Pemigatinib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mehmet Akce
Biliary Obstructive Disease Such as Choledocholithiasis, Benign Biliary Stricture
Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient
Endoscopic retrograde cholangio-pancreatography (ERCP) is advanced endoscopic technique that allows minimally invasive management of biliary and pancreatic disorders.
- Conditions
- Biliary Obstructive Disease Such as Choledocholithiasis, Benign Biliary Stricture, Peri-ampullary Cancer, Bile Duct Cancer Resectable
- Trial name
- NCT02958059
- Testing
- Pacetin® (cefoxitin)
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Inoperable Disease, Bile Duct Cancer
CH-EUS in Diagnosis of Inoperable Bile Duct Tumors
VALIDATION OF THE SUPERIORITY OF CONTRAST ENHANCED ENDOSCOPY TO STANDARD ENDOSCOPY IN THE DIAGNOSIS OF BILE DUCT TUMORS
- Trial name
- NCT05418543
- Testing
- Endoscopic ultrasound with fine needle biopsy
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Pancreas Cancer, Pancreas Neoplasm
Prognostic Factors in Periampullary Tumors and Cysts
The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for…
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Cyst, Pancreatic Fistula
- Trial name
- NCT05155878
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Umeå University
Biliary Tract Cancer (BTC)
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
The objective of SAFIR-IMPACT BTC is to see whether, combining or replacing the standard adjuvant chemotherapy with a targeted therapy matched to the person's cancer, is better than the standard treatment alone in delaying or…
- Trial name
- SAFIR-IMPACT (NCT07745296)
- Testing
- Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine
- Volunteers
- 990 people
- Sponsor
- UNICANCER
Borderline Resectable Carcinoma, Biliary Tract Cancer
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to test feasibility and safety of the combination of tremelimumab and durvalumab plus gemcitabine and cisplatin as a neoadjuvant treatment bridge patients to a curative resection in treatment…
- Trial name
- ESR-22-21719 (NCT06017297)
- Testing
- Durvalumab, Tremelimumab, Gemcitabine
- Sponsor
- Georgetown University
Cholangiocarcinoma, Multiple Myeloma
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to…
- Conditions
- Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
- Trial name
- NCT06340646
- Testing
- Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues
- Where
- United States
- Volunteers
- 990 people
- Sponsor
- Washington University School of Medicine
Cholangiocarcinoma, Liver Cancer
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
To find the highest tolerable dose of infigratinib that can be given in combination with bevacizumab and atezolizumab to patients with advanced/metastatic CCA with a FGFR2 mutation.
- Trial name
- NCT05510427
- Testing
- Infigratinib, Atezolizumab, Bevacizumab
- Sponsor
- M.D. Anderson Cancer Center
Intrahepatic Cholangiocarcinoma, Chemotherapy Effect
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Patients with intrahepatic cholangiocarcinoma (IHC) have relatively aggressive tumors, and the prognosis for most of these patients is dismal.
- Trial name
- TOMCAT (NCT06313203)
- Testing
- Floxuridine, Selective Internal Radiation Therapy (SIRT)
- Where
- Norway
- Volunteers
- 39 people
- Sponsor
- Oslo University Hospital
Cholangiocarcinoma, Hilar, Biliary Stricture
Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent
The purpose of this study is to explore the efficacy and safety of endoscopic scissors cutting nasobiliary ducts in the treatment of malignant hilar biliary tract stenosis
- Conditions
- Cholangiocarcinoma, Hilar, Biliary Stricture, Hilar Cholangiocarcinoma, Klatskin Tumor
- Trial name
- NCT06106750
- Testing
- Endoscopic nasobiliary duct cutting, Bilateral plastic stent
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First People's Hospital of Hangzhou
Cholangiocarcinoma
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or…
- Trial name
- NCT07598318
- Testing
- Becotatug Vedotin, Pucotenlimab, Gemcitabine
- Volunteers
- 164 people
- Sponsor
- Sir Run Run Shaw Hospital
Intrahepatic Cholangiocarcinoma
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated…
- Trial name
- NCT04891289
- Testing
- Gemcitabine, Oxaliplatin, Dexamethasone
- Where
- 11 sites in United States, Netherlands
- Volunteers
- 164 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Cholangiocarcinoma
Open Versus Laparoscopic Ablation of Liver Malignancies
The purpose of this study is to compare laparoscopic ablation to open ablation of liver malignancies regarding complication rates and ablation response as well as quality of life following the surgery.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- OPTIMAL (NCT06304766)
- Testing
- Laparoscopic ablation, Open ablation
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cholangiocarcinoma, Intrahepatic
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor…
- Trial name
- NCT05124002
- Testing
- Recombinant Human Adenovirus Type 5, HAIC of FOLFOX
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Liver Cancer
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020774
- Testing
- gemcitabine hydrochloride, lonafarnib, conventional surgery
- Sponsor
- Jonsson Comprehensive Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00003923
- Testing
- porfimer sodium
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
- Trial name
- NCT00475956
- Testing
- AZD2171, AZD0530
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.